A new study published in Clinical Cancer Research
Title: Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry
Authors: Daniela Miliziano, Julia K. Rotow, Meghanne Lomibao, Arianna Marinello, Helena Bote-de Cabo, Fabrizio Citarella, Lorenza Landi, Massimiliano Cani, Mariana Brandão, Jamie Feng, Sophie Cousin, Andrea De Giglio, Marco Tagliamento, Philippe Rochigneux, Florian Guisier, Lea Ruge, Annarita Avanzo, Francesca Colamartini, Francesco Cortiula, Vladmir Cordeiro de Lima, Antonio Calles, Patricia Iranzo, Barliz Waissengrin, Clarisse Audigier-Valette, Frank Aboubakar, Noemie Simon-Tillaux, Vinicius Ernani, Jordi Remon, Alessio Cortellini, David Planchard, Biagio Ricciuti, Benjamin Besse, Petros Christopoulos, Alexander Drilon, Mihaela Aldea
David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay, shared findings from the study, highlighting the limited effectiveness of subsequent treatment options.
“Real-world data from RET-MAP registry shows 2L plat-pem (+/-IO) achieves a 6.1-mo mrwPFS in RET fusion-NSCLC progressing on selective RET inhibitors, while 3L options yield poor outcomes (rwPFS 1.5 mo), highlighting an urgent need for novel therapies.”
You might be interested in:
FURTHER: Firmonertinib Shows Promising Activity in EGFR PACC-Mutant Advanced NSCLC
